Key clinical point: World Health Organization–defined subgroup was a significant predictor of progression-free survival (PFS) and overall survival (OS) benefit for patients receiving postradiation chemotherapy with procarbazine, lomustine, and vincristine (PCV).

Major finding: Compared with that of the wild-type subgroup, PFS was longer with PCV in the IDH-mutant/non-codeleted subgroup (HR, 0.32; P = .003) and in the IDH-mutant/codeleted subgroup (HR, 0.13; P = .001).

Study details: Post hoc analyses of a phase 3 trial among 106 patients who were successfully profiled for WHO-defined molecular subgroups.

Disclosures: The study was sponsored by the National Cancer Institutes and The Ohio State University. The authors disclosed patents, royalties, and other intellectual property.